Immunologic mechanisms of antitumor activity

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 7, 2002, Pages 5-11

  Foss, Francine M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; B7 ANTIGEN; DNA VACCINE; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; TUMOR VACCINE;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; IMMUNOSURVEILLANCE; METASTASIS; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNOLOGY;

EID: 0036272792     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.33076     Document Type: Article

References (46)

1. A genetic model for colorectal tumorigenesis
2. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
3. Immunity to methylcholanthrene-induced sarcomas
4. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host
5. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor
6. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas
7. Tumor antigens recognized by T lymphocytes
8. Cancer antigens: Immune recognition of self and altered self
9. CD-28-B7 interactions in T-cell activation
10. Cell biology of antigen presentation
11. Signals and signs for lymphocytic responses
12. An innate sense of danger
13. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells
14. The origin and function of tumor associated macrophages
15. Monocytes and macrophages in cancer immunotherapy
16. Transforming growth factor-beta-induced inhibition of T cell function
17. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor
18. The influence of immunosenescence on tumor growth and spread: Lessons from animal models
19. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: Relationship with TIL phenotype and function
20. The mechanism of unresponsiveness to circulating tumor antigen MUC 1 is a block in intracellular sorting and processing by dendritic cells
21. 3 vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines
22. The antitumor immune response problem is a problem of nonself discrimination: Implications for immunotherapy
23. Tumor immunity as autoimmunity: Tumor antigens include normal self proteins which stimulate anergic peripheral T cells
24. Shared human melanoma antigens. Recognition by tumor infiltrating lymphocytes in HLA-A2.1-transfected melanomas
25. The tyrosinase gene encodes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
26. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity
27. Activation of CD4+ T lymphocytes form interleukin 2-deficient mice by costimulatory B7 molecules
28. Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor
29. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
30. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression
31. T-helper-and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector
32. Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen
33. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis
34. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells
35. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
36. Taking lessons from dendritic cells: Multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity
37. Enhanced immune response to the melanoma antigen gpl00 using recombinant adenovirus-transduced dendritic cells
38. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting
39. B7 costimulatory molecules from malignant cells in patients with B-cell chronic lymphoproliferative disorders trigger T-cell proliferation
40. Autologous dendritic cells or cells expressing both B7-1 and MUC1 can rescue tumor-specific cytotoxic T lymphocytes from MUC1-mediated apoptotic cell death
41. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity
42. The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells
43. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2
44. Enhancing the recognition of tumor associated antigens
45. Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans
46. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (V1IR) analysis